Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 7
1996 10
1997 10
1998 19
1999 8
2000 12
2001 9
2002 13
2003 6
2004 12
2005 12
2006 5
2007 12
2008 8
2009 13
2010 13
2011 5
2012 7
2013 4
2014 7
2015 5
2016 5
2017 4
2018 6
2019 5
2020 6
2021 5
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Results by year

Filters applied: . Clear all
Page 1
Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN.
[No authors listed] [No authors listed] Drugs R D. 2004;5(4):236-9. doi: 10.2165/00126839-200405040-00011. Drugs R D. 2004. PMID: 15230633 Review.
Pralmorelin [GPA 748, GHRP 2, growth hormone-releasing peptide 2, KP-102 D, KP 102 LN] is an orally active, synthetic growth hormone-releasing peptide from a series of compounds that were developed by Polygen in Germany and Tulane Univers
Pralmorelin [GPA 748, GHRP 2, growth hormone-releasing peptide 2, KP-102 D, KP 102 LN] is an orall
Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.
Suzuki S, Ruike Y, Ishiwata K, Naito K, Igarashi K, Ishida A, Fujimoto M, Koide H, Horiguchi K, Tatsuno I, Yokote K. Suzuki S, et al. J Endocr Soc. 2022 Jun 6;6(8):bvac088. doi: 10.1210/jendso/bvac088. eCollection 2022 Aug 1. J Endocr Soc. 2022. PMID: 35795807 Free PMC article.
CONTEXT: Growth hormone deficiency (GHD) develops early in patients with hypothalamic-pituitary disorder and is frequently accompanied by other anterior pituitary hormone deficiencies, including secondary adrenal insufficiency (AI). A growth hormone-releasing
CONTEXT: Growth hormone deficiency (GHD) develops early in patients with hypothalamic-pituitary disorder and is frequently accompanied by ot …
Evaluation of growth hormone-releasing peptide-2 for diagnosis of thyrotropin-producing pituitary adenomas.
Kageyama K, Sakihara S, Kameda W, Sugiyama A, Takayasu S, Terui K, Daimon M. Kageyama K, et al. Endocr J. 2018 Oct 29;65(10):1049-1054. doi: 10.1507/endocrj.EJ17-0527. Epub 2018 Jul 5. Endocr J. 2018. PMID: 29973439 Free article.
The diagnosis of TSH-producing adenoma is a challenging problem in clinical endocrinology. Since growth hormone-releasing peptide-2 (GHRP-2) fails to induce TSH secretion in normal subjects, the effect of GHRP-2 on TSH levels was therefore exami …
The diagnosis of TSH-producing adenoma is a challenging problem in clinical endocrinology. Since growth hormone-releasing
Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry.
Okano M, Sato M, Ikekita A, Kageyama S. Okano M, et al. Rapid Commun Mass Spectrom. 2010 Jul 30;24(14):2046-56. doi: 10.1002/rcm.4619. Rapid Commun Mass Spectrom. 2010. PMID: 20552695
GHRP-2 (pralmorelin, D-Ala-D-(beta-naphthyl)-Ala-Ala-Trp-D-Phe-Lys-NH(2)), which belongs to a class of growth hormone secretagogue (GHS), is intravenously used to diagnose growth hormone (GH) deficiency. ...
GHRP-2 (pralmorelin, D-Ala-D-(beta-naphthyl)-Ala-Ala-Trp-D-Phe-Lys-NH(2)), which belongs to a class of growth hormone secretagogue (G …
Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial.
Popławska M, Błażewicz A. Popławska M, et al. Drug Test Anal. 2019 Jan;11(1):162-167. doi: 10.1002/dta.2467. Epub 2018 Aug 14. Drug Test Anal. 2019. PMID: 30051972
Several GHRPs have been developed as drug candidates; however, only one of them, GHRP-2 (Pralmorelin), has received a clinical approval. Nevertheless, they are distributed on the black market and misused by cheating athletes, due to their performance-enhancing effects. ...
Several GHRPs have been developed as drug candidates; however, only one of them, GHRP-2 (Pralmorelin), has received a clinical approv …
Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells.
Chao YN, Sun D, Peng YC, Wu YL. Chao YN, et al. Int J Mol Sci. 2016 Aug 19;17(8):1359. doi: 10.3390/ijms17081359. Int J Mol Sci. 2016. PMID: 27548147 Free PMC article.
We investigated the role of ghrelin in KGN human ovarian granulosa cells using protein kinase C (PKC) activator phorbol 12, 13-didecanoate (PDD) and synthetic ghrelin analog growth hormone releasing peptide-2 (GHRP-2). GHRP-2 attenuated PDD-indu …
We investigated the role of ghrelin in KGN human ovarian granulosa cells using protein kinase C (PKC) activator phorbol 12, 13-didecanoate ( …
Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.
Doi N, Hirotani C, Ukai K, Shimada O, Okuno T, Kurasaki S, Kiyofuji T, Ikegami R, Futamata M, Nakagawa T, Ase K, Chihara K. Doi N, et al. Arzneimittelforschung. 2004;54(12):857-67. doi: 10.1055/s-0031-1297041. Arzneimittelforschung. 2004. PMID: 15646370
KP-102 (D-alanyl-3-(2-naphthyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide dihydrochloride, growth hormone-releasing peptide-2, GHRP-2, pralmorelin, CAS 158861-67-7), is a potent synthetic growth hormone (GH) secretagogue. …
KP-102 (D-alanyl-3-(2-naphthyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide dihydrochloride, growth hormone- …
209 results